同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02410 同源康医药-B

休市中 10-16 16:08:14

3.225

-0.075

-2.27%

最高3.410	最低3.225	成交量20.30万
今开3.300	昨收3.300	日振幅5.61%
总市值12.26亿	流通市值12.11亿	总股本3.80亿
成交额67.27万	换手率0.05%	流通股本3.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":3.225,"timestamp":1792138094388,"preClose":3.3,"halted":0,"volume":203000,"delay":0,"changeRate":-0.022727272727272648,"floatShares":375457818,"shares":380065818,"eps":-0.9390073148526041,"marketStatus":"休市中","change":-0.075,"latestTime":"10-16 16:08:14","open":3.3,"high":3.41,"low":3.225,"amount":672665,"amplitude":0.056061,"askPrice":3.26,"askSize":500,"bidPrice":3.225,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.6590833654993249,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":3.3,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.24591156869855138,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02410","defaultTab":"news","newsList":[{"id":"1188911372","title":"同源康医药-B（02410）2026年第二次临时股东会完成董事改选并通过章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1188911372","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188911372?lang=zh_cn&edition=full","pubTime":"2026-10-16 18:23","pubTimestamp":1792146189,"startTime":"0","endTime":"0","summary":"2026年10月16日，浙江同源康医药股份有限公司在上海召开2026年第二次临时股东会，并公布各项议案的投票表决结果。本次会议共有124,310,501股具有表决权的股份出席，占公司截至会议当日已发行股份总数380,065,818股的32.71%。股东就7名董事重选及公司章程修正案进行表决，全部议案获高票通过。本次股东会由香港中央证券登记有限公司担任监票人，会议的召集、召开与表决程序符合中国《公司法》及公司章程的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675153377","title":"港股早盘持续走低 恒生科技指数大幅下跌2.94% 联想集团（00992）大跌13.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675153377","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675153377?lang=zh_cn&edition=full","pubTime":"2026-10-15 12:13","pubTimestamp":1792037591,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股三大指数早盘持续走低，截至午间收盘，恒生指数下跌1.47%；国企指数下跌1.51%；恒生科技指数大幅下跌2.94%。国恩科技半日涨13.19%，消息面上，据公告显示，集团预期于2026年前9个月取得归属于上市公司股东的净利润约9.5亿-11亿元，同比增长54.45%-78.84%;扣非净利约9.2亿-10.7亿元，同比增长54.14%-79.27%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993772","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034224299.USD","BK1589","LU0543330483.HKD","LU1224709979.USD","LU0417516902.SGD","LU0164880469.USD","HK0000320264.USD","BK1526","LU0359201612.USD","02410","KURE","LU0572944931.SGD","03692","06160","LU0128525689.USD","BK1191","03431","09688","LU0890818403.SGD","TCHI","80992","02600","LU1719994722.HKD","01208","00992","LU1023057109.AUD","LU0049112450.USD","LU0630314457.HKD","LU0320764599.SGD","01258","BK1594","03993","LNVGY","06680","LU2328871848.SGD","LU0029875118.USD","KCAI","LU0672654166.SGD","LU2543165471.USD","VXUS","LU0862451753.SGD","LU0287142896.SGD","HK0000320223.HKD","KTEC","LU1969619763.USD","BK1513","LU0588546209.SGD","LU1785774172.SGD","01378","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115028881","title":"同源康医药-B更新2026年9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028881","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115028881?lang=zh_cn&edition=full","pubTime":"2026-10-06 18:35","pubTimestamp":1791282944,"startTime":"0","endTime":"0","summary":"10月6日，浙江同源康医药股份有限公司披露截至2026年9月30日止的证券变动月报表。公告显示，公司于本报告期内注册股本总额为人民币380,065,818元，与上月相比无新增或减少，未发生购回、注销或库藏股的相关活动。公司确认已符合最低公众持股量要求，未出现违反香港联交所《上市规则》相关规定的情况。截至9月底，公司整体股本无变化，维持在380,065,818股注册资本。公司表示将继续遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167724424","title":"同源康医药-B（02410）10月16日召开第二次临时股东大会 拟重选董事并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1167724424","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167724424?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:49","pubTimestamp":1790758188,"startTime":"0","endTime":"0","summary":"同源康医药-B公布，将于2026年10月16日14:00在上海市徐汇区龙兰路277号东航滨江中心T2幢8楼举行2026年第二次临时股东大会。\\n\\n投票安排方面，所有议案将以投票表决；H股股权登记日为2026年10月16日，股东名册自10月13日至16日暂停过户。H股股东如欲出席并投票，须于10月12日16:30前完成过户手续。会议授权股东可委任代表出席并表决。公司提示与会者需自理交通与住宿费用，并携带有效身份证明入场。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113746815","title":"同源康医药-B：Anchor International Limited减持，好仓比例降至0.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113746815","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113746815?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:12","pubTimestamp":1790068329,"startTime":"0","endTime":"0","summary":"Anchor International Limited于2026年9月20日，因与同源康医药-B（02410）签订的认购协议（日期为2026年7月21日）所载先决条件未获满足或豁免，协议按修订后最后截止日期失效，故不再持有同源康医药-B任何H股股份。Anchor International Limited此次减持前持有同源康医药-B好仓6,322.27万股，占比16.63%；减持后持股量为0股，好仓比例降至0.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668189864","title":"同源康医药-B(02410)根据一般授权发行H股的认购协议失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2668189864","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668189864?lang=zh_cn&edition=full","pubTime":"2026-09-20 19:08","pubTimestamp":1789902483,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，有关与齐鲁达成许可及合作以及拟向认购方发行 6322.27万股H股相关事宜。经审慎考虑当前市场状况及股份价格的近期变动，本公司与齐鲁已相互同意不再进一步延长经修订最后截止日期，而认购协议将因此根据其条款于经修订最后截止日期结束时失效。关于公告中所披露的许可及合作协议以及供应及商业化协议，齐鲁及本公司将继续遵守其各自于该等协议项下的义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","BK1574","09939","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128543055","title":"同源康医药-B（02410）63,222,744股H股认购协议于2026年9月20日失效","url":"https://stock-news.laohu8.com/highlight/detail?id=1128543055","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128543055?lang=zh_cn&edition=full","pubTime":"2026-09-20 19:05","pubTimestamp":1789902328,"startTime":"0","endTime":"0","summary":"2. 该认购事项原披露于2026年7月21日及2026年8月20日的公告，并需在经修订最后截止日期前满足或豁免若干先决条件方可完成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121235752","title":"同源康医药-B公布2026年第二次临时股东大会H股过户安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1121235752","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121235752?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:40","pubTimestamp":1789720800,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司9月18日公告称，为确定股东出席公司2026年第二次临时股东大会并在会上行使表决权的资格，公司将于2026年10月13日至10月16日暂停办理H股股份过户登记手续。同源康医药-B表示，将适时发布进一步公告，并向股东寄发载有临时股东大会各项决议案详情的通函、会议通知及委任代表表格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961761","title":"董事长兼总裁吴豫生增持同源康医药-B(02410)12万股 每股作价3.486港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668961761?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:38","pubTimestamp":1789645100,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月16日，董事长兼总裁吴豫生增持同源康医药-B(02410)12万股，每股作价3.486港元，总金额约为41.83万港元。增持后最新持股数目约为1.25亿股，最新持股比例为32.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","159938","BK1161","BK1574","09939","BK1515","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147211730","title":"同源康医药-B：吴豫生增持，好仓比例升至32.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147211730","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147211730?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:41","pubTimestamp":1789638085,"startTime":"0","endTime":"0","summary":"吴豫生于2026年9月16日在联交所场内以每股均价3.486港元买入同源康医药-B（02410）12.00万股，涉资约41.83万港元，属场内主动交易，即在二级市场直接买卖股份。吴豫生此次增持前持有同源康医药-B好仓1.25亿股，占比32.86%；增持后持股量为1.25亿股，好仓比例升至32.89%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171437411","title":"同源康医药-B：吴豫生增持，好仓比例升至32.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171437411","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171437411?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:41","pubTimestamp":1789551695,"startTime":"0","endTime":"0","summary":"吴豫生于2026年9月15日在联交所场内以每股均价3.497港元买入同源康医药-B25.00万股，涉资约87.42万港元，属场内主动交易，即在二级市场直接买卖股份。吴豫生此次增持前持有同源康医药-B好仓1.25亿股，占比32.8%；增持后持股量为1.25亿股，好仓比例升至32.86%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641986","title":"董事长兼总裁吴豫生增持同源康医药-B(02410.HK)40万股 每股作价约2.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667641986?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:07","pubTimestamp":1789470429,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1574","BK1515","02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196177221","title":"同源康医药-B：吴豫生增持，好仓比例升至32.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196177221","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196177221?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:24","pubTimestamp":1789464255,"startTime":"0","endTime":"0","summary":"吴豫生于2026年9月14日以每股均价2.8157港元买入同源康医药-B股份40.00万股，涉资约112.63万港元。吴豫生此次增持前持有同源康医药-B好仓1.24亿股，占比32.69%；增持后持股量为1.25亿股，好仓比例升至32.8%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690691","title":"港股异动 | 同源康医药-B(02410)涨逾10% 大股东增持提振市场信心 此前核心品种已顺利获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690691","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667690691?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:02","pubTimestamp":1789437751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早震荡走高，截至发稿，涨10.1%，报3.38港元，成交额389.48万港元。此外，今年8月底，同源康医药披露其核心品种顺利获批，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得NMPA批准，在国内附条件上市，适应症为具有EGFR 19DEL或L858R置换突变，并伴有CNS转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","159938","09939","BK4588","VXUS","02410","BK1161","BK4585","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667670666","title":"董事长兼总裁吴豫生增持同源康医药-B(02410)17万股 每股作价约2.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667670666","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667670666?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:07","pubTimestamp":1789384024,"startTime":"0","endTime":"0","summary":"9月11日，董事长兼总裁吴豫生增持同源康医药-B(02410)17万股，每股作价2.7036港元，总金额约为45.96万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260914/20260914190726_24966.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260914/20260914190726_24966.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09939","BK1574","02410","EWH","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151739536","title":"同源康医药-B：吴豫生增持，好仓比例升至32.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151739536","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151739536?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:21","pubTimestamp":1789377675,"startTime":"0","endTime":"0","summary":"吴豫生于2026年9月11日以每股均价2.7036港元买入同源康医药-B（02410）股份17.00万股，涉资约45.96万港元。吴豫生此次增持前持有同源康医药-B好仓1.24亿股，占比32.65%；增持后持股量为1.24亿股，好仓比例升至32.69%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130989948","title":"同源康医药-B：吴豫生增持，好仓比例升至32.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130989948","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130989948?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:32","pubTimestamp":1789119134,"startTime":"0","endTime":"0","summary":"吴豫生于2026年9月10日以每股均价2.9699港元买入同源康医药-B股份22.50万股，涉资约66.82万港元。吴豫生此次增持前持有同源康医药-B好仓1.24亿股，占比32.59%；增持后持股量为1.24亿股，好仓比例升至32.65%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165686058","title":"同源康医药-B2026年中期营收0元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165686058","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165686058?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:42","pubTimestamp":1789116120,"startTime":"0","endTime":"0","summary":"2026年上半年，同源康医药-B营收为0元，与上年同期持平。\n在成本结构方面，研发投入为94.94百万元，同比增长7.0%。管理费用为62.55百万元，同比增长61.3%。两项费用增幅主要来自于本期人员成本以及专业服务费增加等因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"同源康医药-B2026年中期营收0元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510406","title":"港股异动 | 同源康医药-B(02410)涨超9% 董事长增持彰显长期发展信心 创新EGFR-TKI 重磅获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510406","media":"智通财经","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666510406?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:01","pubTimestamp":1789095677,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早拉升逾9%，截至发稿，涨9.7%，报2.94港元，成交额963.22万港元。消息面上，同源康医药昨晚公布，董事长、执行董事兼总裁吴豫生告知，于本月8至10日期间，于公开市场购入63.5万股H股，占已发行股本总额约0.17%，总代价约209万港元。公司表示，吴豫生已告知未来可能继续根据市场情况购买股份。此次进一步增持股份彰显对集团未来发展前景的信念及充分信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1515","BK1161","BK4585","BK1574","09939","VXUS","02410","KCAI","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594669","title":"同源康医药-B(02410.HK)获董事长吴豫生增持63.5万股H股 涉资约209万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594669","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666594669?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:47","pubTimestamp":1789051624,"startTime":"0","endTime":"0","summary":"格隆汇9月10日丨同源康医药-B(02410.HK)公告，公司董事长、执行董事兼总裁吴豫生已告知公司，于2026年9月8日至2026年9月10日期间，其于公开市场购入63.5万股公司H股(占公司已发行股本总额约0.17%)，总代价约为209万港元。吴豫生已告知公司，其未来可能继续根据市场情况购买公司股份。目前预计其将在此基础上进一步购买股份的总金额不超过300万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260910/32366677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02410","09939","BK1574","159938","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0877},{"period":"1month","weight":-0.0825},{"period":"3month","weight":-0.56},{"period":"6month","weight":-0.7079},{"period":"1year","weight":-0.7998},{"period":"ytd","weight":-0.754}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}